December 14, 2023
Torii Pharmaceutical said on December 13 that it has struck a license deal with Denmark-based ALK-Abelló, obtaining the exclusive rights to develop and commercialize its sublingual allergen immunotherapy drug Grazax in Japan for the treatment of grass pollen allergies. The...read more